Author

Zheng-Kui Sun

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.

Importance Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast cancer. Objective To compare trastuzumab rezetecan vs physician's choice of chemotherapy in patients...

Y. Fan, Yun-Jiang Liu, Yong-Sheng Wang et al. · Journal of the American Medi... · 1 citation

Review Sep 2026

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

PURPOSE To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC). METHODS In this phase III, open-label, multicenter trial (ClinicalTrials.gov...

Jian Zhang, Q. Ouyang, Qing-Yuan Zhang et al. · Journal of Clinical Oncology · 0 citations

Open access Sep 2026

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study

Sacituzumab tirumotecan (sac-TMT) is a novel anti-trophoblast cell-surface antigen 2 antibody-drug conjugate and has been approved for second-line and subsequent treatment of metastatic triple-negative breast cancer (TNBC) in China. This post-hoc exploratory study aims to further characterize the safety profile of sac-...

Ying Fan, Q. Ouyang, Yong-Mei Yin et al. · Breast Cancer Research · 0 citations